Redeye notes Fluoguide announcing phase IIa top-line data with FG001 in head and neck cancer.
Bra Q3-rapport Bolaget gladde igen med att visa starka siffror för det tredje kvartalet.
Redeye comments on Flexion Mobile’s preliminary figures for Q3-Q4 and its revised full year guidance...
Dynava is entrusted by Region Stockholm for an additional two years to operate transportation servic...
Redeye comments on BioInvent’s TNFR2 project BI-1808 after strong phase I results presented at SITC ...
Physitrack will release its Q3 2023 report on 14 November at 08:00 and host a conference call at 10:...
3.5pp q-o-q margin expansion a strong statement Adj.
Q-linea is making progress, including commercial evaluations and partner discussions for the US mark...
Redeye is encouraged to see the progress made by Scandinavian ChemoTech in the Q3 2023 report, which...
Marimekko reports its Q3 result 8th of November. We expect pick-up in growth driven by strong overal...
Redeye comments on Alelion’s decision to file for bankruptcy.
Redeye maintains its positive view despite lowering its Base Case and forecasts significantly.
Movinn published on November 3rd the company’s Q3-report for 2023.
Blandat utfall i Q3 I det stora hela var siffrorna i Q3-rapporten relativt odramatiska.
ChargePanel AB (publ) meddelade den 2 november att bolaget har ingått ett samarbete med Charge4Go AB...
Redeye remains firm in its view that Acconeer will not need any additional capital injections.
Minor estimate changes Gross margin improvements still on the horizon '24e lease adj.
Redeye provides an initial take on Optomed’s Q3 2023 report.
Continued headwinds in Denmark and Germany in Q3 Underlying '24e-'25e EBITA cut 12-9%, but neutral i...
Fiskars arranged its CMD event yesterday where it offered insights to its strategy and to how reach ...
